C4 Therapeutics, Inc. (CCCC) stock

CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3018% above fair value

$2.76−0.01 (-0.36%)

Close on Nov 13, 2026Market cap $339.55MP/E –Yield –

C4 Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

C4 Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in C4 Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CCCC.

Revenue growth7.2% · median -34.3%

Operating margin-315.9% · median -396.0%

Net margin-282.2% · median -344.2%

Advertisement
300 × 250

See a number that looks wrong?